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Abstract
Background: Angiotensin-(1–12) [Ang-(1–12)] functions as an endogenous substrate for the productions of Ang II and Ang-
(1–7) by a non-renin dependent mechanism. This study evaluated whether Ang-(1–12) is incorporated by neonatal cardiac
myocytes and the enzymatic pathways of
125I-Ang-(1–12) metabolism in the cardiac myocyte medium from WKY and SHR
rats.
Methodology/Principal Findings: The degradation of
125I-Ang-(1–12) (1 nmol/L) in the cultured medium of these cardiac
myocytes was evaluated in the presence and absence of inhibitors for angiotensin converting enzymes 1 and 2, neprilysin
and chymase. In both strains uptake of
125I-Ang-(1–12) by myocytes occurred in a time-dependent fashion. Uptake of intact
Ang-(1–12) was significantly greater in cardiac myocytes of SHR as compared to WKY. In the absence of renin angiotensin
system (RAS) enzymes inhibitors the hydrolysis of labeled Ang-(1–12) and the subsequent generation of smaller Ang
peptides from Ang-(1–12) was significantly greater in SHR compared to WKY controls.
125I-Ang-(1–12) degradation into
smaller Ang peptides fragments was significantly inhibited (90% in WKY and 71% in SHR) in the presence of all RAS enzymes
inhibitors. Further analysis of peptide fractions generated through the incubation of Ang-(1–12) in the myocyte medium
demonstrated a predominant hydrolytic effect of angiotensin converting enzyme and neprilysin in WKY and an additional
role for chymase in SHR.
Conclusions/Significance: These studies demonstrate that neonatal myocytes sequester angiotensin-(1–12) and revealed
the enzymes involved in the conversion of the dodecapeptide substrate to biologically active angiotensin peptides.
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Introduction
Advances in the biochemical physiology of tissue renin
angiotensin systems (RAS) now document the existence of
alternate pathways for the generation and metabolism of
angiotensin peptides. Adding to this knowledge are new findings
showing that additional alternate mechanisms exist for the
formation of angiotensin peptides upstream from angiotensin I
(Ang I). Nagata et al. [1] identified an extended form of Ang I
present in multiple organs of Wistar rats. The peptide named
‘‘proangiotensin-(1–12)’’ contained the sequence of Ang I plus -
Leu
11-Tyr
12 at the C-terminus. In keeping with the nomenclature
approved by the Council for High Blood Pressure Research [2] we
refer to proangiotensin-(1–12) as angiotensin-(1–12) [Ang-(1–12)].
In their studies Nagata et al. [1] reported the capacity of the
docadecapeptide to serve as a functional substrate for the
production of angiotensin II (Ang II). The delivery of synthetic
Ang-(1–12) either systemically or following application to isolated
rat aorta induced pressor or vasoconstrictor responses that were
eliminated by prior administration of the angiotensin converting
enzyme (ACE) inhibitor captopril or the Ang II AT1 receptor
antagonist, candesartan. Intrigued by the potential significance of
Ang-(1–12) as an endogenous alternate precursor for the formation
of Ang I, a series of studies from our laboratory documented the
expression of Ang-(1–12) in the heart and kidney of Wistar Kyoto
(WKY) and spontaneously hypertensive (SHR) rats [3] and
showed in the isolated heart of three normotensive (Sprague
Dawley, Lewis, and WKY) and two hypertensive (congenic
mRen2.Lewis and SHR) rats that cardiac formation of Ang I,
Ang II, and angiotensin-(1–7) [Ang-(1–7)] occurred through
cleavage of Ang-(1–12) via a non-renin pathway. [4] Additional
evidence for a renin independent formation of Ang II from Ang-
(1–12) was demonstrated in anephric rats as the fall in circulating
Ang I and Ang II was associated with increased cardiac content of
Ang-(1–12) and Ang II 48 h post-bilateral nephrectomy. [5]
PLoS ONE | www.plosone.org 1 January 2011 | Volume 6 | Issue 1 | e15759The scientific questions addressed in these studies are: a)- is
Ang-(1–12) contained within and incorporated by neonatal cardiac
myocytes?; b)- what are the routes of Ang-(1–12) metabolism in the
medium of serum deprived cardiac myocytes?; and c)- is there a
differential incorporation and routes of metabolism in normoten-
sive WKY and SHR rats?
Results
Myocyte Uptake of
125I-Ang-(1–12)
Total cellular uptake of 1 nM
125I-Ang-(1–12) by WKY and
SHR myocytes were investigated in the presence of all RAS and
peptidases inhibitors (amastatin, bestatin, benzyl succinate and
PCMB). Figure 1 show that
125I-Ang-(1–12) was incorporated by
cultured myocytes in a time-dependent fashion in both WKY and
SHR. Importantly, the data shown in Figure 1 reveals that the rate
of
125I-Ang-(1–12) uptake at all time points was significantly higher
in SHR as compared to WKY myocytes. Based on cellular counts
of
125I-Ang-(1–12) from the myocytes’ lysate, peak cellular uptake
of
125I-Ang-(1–12) averaged 0.7860.08 fmol?mg protein
21?min
21
in SHR myocytes and 58% less in WKY myocytes
(0.4660.07 fmol?mg protein
21?min
21;p ,0.001). Cellular counts
of
125I-Ang-(1–12) in both WKY and SHR cell lysate were
significantly decreased (around 50%) by a 10
3-fold excess amount
of unlabeled Ang-(1–12). These findings confirm and extend our
initial report for an increased content of Ang-(1–12) in the heart of
SHR through independent assessment of peptide content by both
immunohistochemistry and radioimmunoassay (RIA) measure-
ments. [3]
The cell lysate (cytosolic fraction) from cardiac myocytes
samples was also analyzed by HPLC/radioisotope detection to
ensure that intact
125I-Ang-(1–12) is internalized by these cells.
Figure 2 shows that the majority of the cell-associated radioactivity
eluted at a retention time identical to
125I-Ang-(1–12) in cardiac
myocytes lysates of both strains in the absence (No RAS inhibitor
group) and in the presence of all RAS inhibitors (ACE, NEP, ACE2,
and chymase). These data confirmed that intact
125I-Ang-(1–12) is
incorporated into the cardiac myocytes.
Total cellular internalized content of
125I-Ang-(1–12) in the
presence or absence of all RAS enzyme inhibitors was calculated
by analyzing the
125I-Ang-(1–12) peak of WKY and SHR
myocytes. In the presence of all RAS inhibitors, the cellular
content of
125I-Ang-(1–12) was 3.660.3% in WKY and 5.260.5%
in SHR of the total loaded content of radiolabeled Ang-(1–12).
However, in the absence of RAS inhibitors (No RAS inhibitor group),
the cellular content of
125I-Ang-(1–12) was significantly lower
(2.160.4% in WKY and 2.560.3% in SHR; p,0.05) as compared
to the total
125I-Ang-(1–12) added to the reaction mixture.
125I-Ang-(1–12) Metabolism
Metabolic products of
125I-Ang-(1–12) were analyzed by HPLC
in the cultured medium of WKY and SHR cardiac myocytes in the
absence andinthe presenceofinhibitorsforACE,NEP,ACE2,and
chymase. In the absence of RAS enzyme inhibitors,
125I-Ang-(1-12)
was processed into Ang I, Ang II, Ang-(1–7), Ang-(1–5) and other
smaller angiotensin peptide fragments in both WKY and SHR
(Figure 3). In contrast, the addition of all RAS enzyme inhibitors
reduced formation of angiotensin peptides and revealed a larger
peak of
125I-Ang-(1–12) in the medium of both strains. These data
demonstrate the existence of Ang-(1–12) convertases in the medium
collected from neonatal cardiac myocytes.
Contributions of Specific RAS Enzymes in
125I-Ang-(1–12)
Metabolism
Table 1 summarizes the effects of selective inhibition of ACE,
NEP, ACE2, and chymase on
125I-Ang-(1–12) metabolism in the
culture medium from both WKY and SHR. When the study was
performed in the absence of RAS inhibitors, a significantly larger
percentile of
125I-Ang-(1–12) was rapidly metabolized into Ang
fragments [Ang I, Ang II, Ang-(1–7), Ang-(1–4) & smaller
peptides] in the medium by WKY and SHR myocytes [only
26% and 8% of
125I-Ang-(1–12) remained un-metabolized in the
medium, respectively]. However, in the presence of all RAS
inhibitors, 90% and 71% of
125I-Ang-(1–12) remained in the
medium of WKY and SHR cardiac myocytes, respectively. Table 1
also shows that SHR medium from cultured myocytes degraded
125I-Ang-(1–12) at a rate faster than the medium from WKY. Sixty
minute after addition of the labeled peptide the percentage of
125I-
Ang-(1–12) detected in the SHR medium is 3-fold less than in
WKY; this is associated with lower % fractions of Ang II and
significantly higher % fractions of Ang-(1–4) and smaller peptide
fragments. In addition, the differences in the percent of
125I-Ang-
(1–12) and Ang II remaining at the end of the incubation period
between WKY and SHR was not affected by the presence of the
inhibitor cocktail (Table 1).
In the absence of ACE or the NEP inhibitor, only 41% and
58% of the un-metabolized form of
125I-Ang-(1–12) remained in
the medium collected from WKY cultured myocytes, respectively,
while lower percentages of
125I-Ang-(1–12) were found in the
medium collected from SHR (Table 1). Removal of lisinopril from
the cultured myocytes medium resulted in similar generations of
Ang I and Ang II in both WKY and SHR. Absence of either
chymostatin or the ACE2 inhibitor (MLN-4760) did not
substantially changed the presence of
125I-Ang-(1–12) in the
medium from WKY cardiac myocytes.
Although, the absence of the ACE2 inhibitor did not change the
125I-Ang-(1–12) level in the medium of the SHR myocytes, removal
Figure 1. Uptake of Ang-(1–12) by neonatal cardiac myocytes.
Time dependent increase in cellular uptake of
125I-Ang-(1–12) in
cultured neonatal SHR cardiac myocytes (solid line) as compared to
WKY (dotted line) in the presence of all RAS enzymes inhibitors. Cellular
internalization of
125I-Ang-(1–12) is expressed as fmol
21 xm g
21 protein.
Each value represents the mean 6 SE of three or more independent
assays. In these experiments, WKY and SHR myocytes were treated with
all inhibitor cocktail containing lisinopril (ACE inhibitor), SCH39370 (NEP
inhibitor), MLN-4760 (ACE2 inhibitor), and chymostatin (chymase
inhibitor), peptidase inhibitors (amastatin, bestatin & benzyl succinate),
and PCMB each added at a dose of 10 mM. *Significantly different
(P,0.001) from the mean of the corresponding time point of WKY.
doi:10.1371/journal.pone.0015759.g001
Angiotensin-(1–12) Metabolism in Cardiac Myocytes
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and Ang II (21%).
125I-Ang-(1–12) metabolism by SHR myocytes
was significantly increased in the absence of chymostatin.
Based on fraction conversions (see Methods), Figure 4 shows the
relative contributions of each enzyme to
125I-Ang-(1–12) metabolism
by WKY and SHR cardiac myocytes. The contribution of ACE,
NEP, or chymase enzyme activity to the hydrolysis of
125I-Ang-(1–
12) was significantly higher in SHR (ACE=17.361.0 fmol?mg
protein
21?min
21; neprilysin=13.060.7 fmol?mg protein
21?min
21;
chymase=3.760.1 fmol?mg protein
21?min
21, all P,0.05 vs.
corresponding WKY) as compared to WKY (ACE=11.960.7 f-
mol?mg protein
21?min
21; neprilysin=7.260.4 fmol?mg pro-
tein
21?min
21;c h y m a s e = 1 . 5 60.1 fmol?mg protein
21?min
21). No
significant difference in ACE2 enzyme activity was noted between
SHR and WKY (0.8360.3 fmol?mg protein
21?min
21 and
0.560.1 fmol?mg protein
21?min
21, respectively).
Endogenous Localization of Ang-(1–12) in Cardiac
Myocytes
The endogenous presence of Ang-(1–12) was visualized by
fluorescent staining within the cultured cardiac myocytes of both
WKY (top panel) and SHR (bottom panel) in three or more
specimens obtained from separate preparations of neonatal cardiac
myocytes. As shown in Figure 5, the immunoreactive fluorescent
green staining is expressed in the cytoplasm of cardiac myocytes of
bothWKY(Figure5 A)and SHR (Figure5B).Pre-adsorptionofthe
antibody with 10 mM of synthetic rat Ang-(1–12) peptide blocked
the immunoreactive fluorescent green staining of endogenous Ang-
(1–12) content in WKY (Figure 5 C) and markedly reduced the
immunofluorescence in the myocytes from SHR (Figure 5 D). No
green fluorescent staining (only blue staining of nuclei) were found
in both WKY and SHR myocytes independently treated with
normal Donkey serum in the absence of Ang-(1–12) primary
antibody (served as negative controls) (data not shown).
Angiotensinogen and Renin Expression in Cardiac
Myocytes
Angiotensinogen protein expression in the neonatal WKY and
SHR cardiac myocytes maintained in serum-free medium for
48 hours was determined by Western blot analysis using
appropriate antibodies. The angiotensinogen protein (60 KD
band size) was present in both WKY and SHR myocytes
Figure 2. Effect of inhibitors on Ang-(1–12) metabolism in cardiac myocytes. Characterization by high pressure liquid chromatography of
cellular
125I-Ang-(1–12) products internalized by 24-h serum deprived cultured neonatal WKY (A and B) and SHR (C and D) cardiac myocytes in the
presence of all inhibitors cocktail (containing lisinopril, SCH39370, MLN-4760, chymostatin, amastatin, bestatin, benzyl succinate and PCMB) andi n
the absence of RAS inhibitors (containing only amastatin, bestatin, benzyl succinate & PCMB) each added at a dose of 10 mM. Before adding the
125I-Ang-(1–12), the cultured cardiac myocytes were pre-incubated with inhibitors for 15 min at 37uC. The arrow indicates the peak area of
125I-Ang-(1–12).
doi:10.1371/journal.pone.0015759.g002
Angiotensin-(1–12) Metabolism in Cardiac Myocytes
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sion level with loading control (EF-1a), we observed a tendency
for a decreased level of angiotensinogen protein in 48 hours
serum deprived neonatal cultured SHR myocytes as compared to
WKY. Renin expression in these samples was also analyzed by
using a well-characterized renin antibody obtained from Dr.
Figure 3. Patterns of Ang-(1–12) metabolism in the medium collected from cardiac myocytes. HPLC characterization of
125I-Ang products
generated in the medium of cultured neonatal WKY (A) and SHR (B) cardiac myocytes exposed to
125I-Ang-(1–12) at 37uC for 60 min in the presence
(solid line) and absence (dotted line) of the RAS inhibitors cocktail. Other conditions as described in Figure 2.
doi:10.1371/journal.pone.0015759.g003
Table 1. Comparative effects of selective enzyme inhibition on
125I-Ang-(1–12) metabolism in medium of cultured neonatal wky
and shr cardiac myocytes.
Peptides
No RAS
Inhibitors
+All RAS
Inhibitors Minus Lisinopril Minus SCH39370 Minus MLN-4760 Minus Chymostatin
Wistar Kyoto Rats
Ang-(1–12)* 2663
a 90624 1 67
b 5864
b 92628 7 63
Ang I 1461
a 4611 8 65
b 7623 615 62
Ang II 3765
a 3613 3 64
b 6632 613 61
Ang-(1–5) 3611 612 612 611 611 61
Ang-(1–7) 7621 614 617 61
b 1611 61
Ang-(1–4) & smaller peptides 1363
a 1612 612 0 62
b 1613 61
Spontaneous Hypertensive Rats
Ang-(1–12)* 862
a,c 7162
c 2764
b 3864
b,c 84665 1 65
b,c
Ang I 10634 611 8 62
b 8615 622 0 63
b,c
Ang II 2965
a 1462
c 4264
b 7626 632 1 64
c
Ang-(1–5) 6611 613 611 612 612 61
Ang-(1–7) 10624 623 611 3 62
b 2612 61
Ang-(1–4) & smaller peptides 3765
a,c 6627 633 3 67
b 3614 61
Values are expressed as % (Mean 6 SE) of Ang-(1–12) unmetabolized* and Ang peptides (%) generated from
125I-Ang-(1–12) in the cultured medium incubated for
60 min at 37uC to WKY or SHR myocytes with or without the presence of RAS inhibitors. No inhibitors group: Only aminopeptidases inhibitors (amastatin & bestatin) and
carboxypeptidases inhibitor (benzyl succinate); All inhibitors group: Aminopeptidases and carboxypeptidases inhibitors + RAS inhibitors (lisinopril, SCH39370, MLN-4760
& chymostatin); Minus RAS inhibitor groups: One of the RAS inhibitor (lisinopril/SCH39370/MLN-4760/chymostatin) omitted at a time from all inhibitors group. All values
are expressed as (%) and are the average of three or more independent assays.
*Percent of
125IAng-(1–12) parent control remained un-metabolized in the medium exposed to WKY or SHR myocytes for 60 min at 37uC.
aSignificantly different (P,0.05) in No RAS inhibitors group vs. corresponding WKY or SHR group of +All RAS inhibitors.
bSignificantly different (P,0.05) vs. corresponding group of +All RAS inhibitors.
cSignificantly different (P,0.05) vs. corresponding WKY.
doi:10.1371/journal.pone.0015759.t001
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PLoS ONE | www.plosone.org 4 January 2011 | Volume 6 | Issue 1 | e15759Tadashi Inagami (Nashville, TN). No active renin protein band
(37–40 KD) was detected in both WKY and SHR myocytes.
These findings further suggest that Ang-(1–12) generated in
myocytes from angiotensinogen by a non-renin dependent
pathways.
Discussion
Prior experimental [1,3–8] and pilot studies in human atrial
tissue [9] demonstrated that Ang-(1–12) may serve as an alternate
pathway for the generation of angiotensin peptides, a pathway that
may be of relevance in situations of suppressed renin activity or
secretion, as well as possibly acting as an intracellular precursor for
the formation of angiotensin peptides. In this study we report for
the first time the presence of Ang-(1–12) in neonatal cardiac
myocytes from both WKY and SHR together with a time
dependent intracellular incorporation of labeled Ang-(1–12) in
both strains. Intact uptake of
125I-Ang-(1–12) was significantly
higher in SHR, a finding that agrees with the previous
demonstration of increased Ang-(1–12) content in the myocardium
of adult hypertensive rats by both immunohistochemistry and
RIA. [3] Assessment of the hydrolysis of
125I-Ang-(1–12) in the
presence and absence of inhibitors for ACE, NEP, ACE2, and
chymase revealed a primary involvement of ACE and NEP in
WKY and an additional important contribution of chymase in
SHR. This finding is in keeping with reports showing augmented
chymase expression and increased chymostatin-inhibitable angio-
tensin-converting activity in SHR. [10] The increased hydrolytic
effects of chymase on
125I-Ang-(1–12) metabolism in SHR was
associated with a greater processing activity of ACE and NEP.
These findings agree with previous studies suggesting increased
expression and activity of the cardiac renin angiotensin system in
SHR. [10]
Although further work will be necessary to elucidate potential
differences in the processing and incorporation of extracellular
Ang-(1–12) between neonatal and adult cardiac myocytes previous
Figure 4. Enzyme activities in WKY and SHR cardiac myocytes.
Relative contributions of each enzyme to the
125I-Ang-(1–12) metab-
olism by WKY and SHR cardiac myocytes documents higher enzymatic
activity in SHR. These enzymes activity were calculated based on
peptide fractions generated from Ang-(1–12) under various RAS
inhibitors condition used (see Material and Methods). Abbreviations
are: ACE, angiotensin converting enzyme; NEP, neprilysin, ACE2,
angiotensin converting enzyme 2. Values are means 6 SE. *, p,0.05.
doi:10.1371/journal.pone.0015759.g004
Figure 5. Characteristics of Ang-(1–12) expression in cultured myocytes. Representative examples of fluorescent photomicrographs of Ang-
(1–12) immunoreactivity of the cultured myocytes (maintained for 48 hours in serum-deprived medium) from WKY (A and C; top panel) and SHR (B
and D; bottom panel) with protein A purified Ang-(1–12) polyclonal antibody (1:100 dilution). (A and B) represents the fluorescent staining of
endogenous Ang-(1–12) with antibody while (C and D) illustrates the blocking of fluorescent staining of cardiac myocytes after preadsorption of the
antibody with 10 mM of synthetic rat Ang-(1–12) peptide. Magnification, X400.
doi:10.1371/journal.pone.0015759.g005
Angiotensin-(1–12) Metabolism in Cardiac Myocytes
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maturation of SHR ventricular myocytes compared to WKY rats
during the first postnatal week. [11] This is associated with the
presence of earlier development of binucleate myocytes and
initiation of hypertrophic myocyte growth in SHR. [12]
The use of a radiolabeled form of Ang-(1–12) allowed for a
precise and sensitive quantification of the products generated by
the hydrolysis of Ang-(1–12). The drugs were given in doses
sufficient to block
125I-Ang-(1–12) metabolism by at least 90%. As
documented elsewhere, [13–15] inclusion of amastatin, bestatin,
benzyl succinate, and PCMB in all processed samples was an
added precaution to prevent the further degradation of angioten-
sin peptides by aminopeptidases and carboxypeptidases into
smaller fragments.
The heart is an organ where local formation of Ang II is
implicated to regulate cardiac remodeling due to increased
afterload or ischemia. [16,17] Central to this concept is the
demonstration that Ang II can be produced locally and function as
a paracrine [16,17] or autocrine factor. [18] Through the use of
radiolabeled
125I-Ang I and
125I-Ang II van Kats et al. [19]
concluded that most of the Ang I and Ang II found in the heart
was produced locally. These findings are reinforced by the recent
demonstration of increased Ang II synthesis in cardiac myocytes
from diabetic rats. [20] In the SHR, increased activity of the RAS
is found in the heart [21,22] and the kidneys [23] while in cultured
newborn SHR heart cells, increased uptake of
3H-proline by Ang I
and Ang II was abolished by blockade with either an ACE
inhibitor or an AT1 receptor antagonist. [24] The latter findings
suggest an intrinsic increase in protein uptake by SHR myocytes, a
finding that is in keeping with the current observations of
differences in the rate of
125I-Ang-(1–12) incorporation in WKY
and SHR myocytes.
A further insight into the functional significance of local RAS is
expanded by our finding of an increased incorporation of intact
125I-Ang-(1–12) in cardiac myocytes from cultured neonatal cells
of SHR. The HPLC analysis of cell lysate showed that intact Ang-
(1–12) is internalized by cardiac myocytes, although the amount
internalized represents a small fraction of total loaded
125I-Ang-(1–
12) (,5.2% in SHR & ,3.6% in WKY). Further, we report
around 50% inhibition of cellular internalization of radiolabeled
Ang-(1–12) in the presence of excess cold Ang-(1–12) [Iodine-
unlabeled Ang-(1–12); 10
3 mM]. We suggest that the failure to
achieve higher inhibition may be due to differences in binding
affinity between cold Ang-(1–12) and
125I-Ang-(1–12) or the
potential existence of several uptake mechanisms. This interpre-
tation is in keeping with the finding that no more than only 50% of
bound angiotensinogen could be displaced from human renal
tubular epithelial cells [25]. As in their study, Ang-(1–12) as an
extended form of Ang I, might bind to a low affinity receptor or
alternatively to the same angiotensinogen receptor characterized
by Yayama et al., [26] and Pan et al. [25]. In addition, Mineo
et al., [27] reported a similar 50% inhibition of
125I-Ang II in the
presence of unlabeled Ang II in endothelial cell monolayers. They
interpreted these findings as suggesting that about 50% of Ang II
was transported via an intracellular pathway while the remainder
was accounted for non-specific transport. The augmented
incorporation of Ang-(1–12) into SHR myocytes agrees with the
reported observation of increased incorporation of
3H-uradine and
14C-leucine into 10-day-old SHR heart cells. [28] The process
appears to remain present in older animals as adult SHR showed
increased Ang-(1–12) expression as determined independently by
immunostaining of left ventricular sections with a selective Ang-(1–
12) antibody and additional measures of Ang-(1–12) content by
radioimmunoassay. [3]
Figure 6. Angiotensinogen protein expression in WKY and SHR myocytes. Western blotting of angiotensinogen (AOGEN) protein
expression in neonatal WKY and SHR myocytes (maintained for 48 hours in serum-deprived medium) by using an antibody directed against an
epitope on the NH2-terminus region of the angiotensinogen protein (residues 44–56). The myocytes cell lysate (50 mg protein) were separated by gel
electrophoresis and transferred on PVDF. Equal protein loading was confirmed by EF-1a detection in cell lysates. Relative O.D. (AOGEN/EF-1 a)i s
represented as the mean 6 SE of three samples from each group.
doi:10.1371/journal.pone.0015759.g006
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PLoS ONE | www.plosone.org 6 January 2011 | Volume 6 | Issue 1 | e15759In the controlled environment of a cell culture system, neonatal
cardiac myocytes of SHR and WKY metabolized
125I-Ang-(1–12)
into Ang I, leading to sequential production of Ang II, Ang-(1–7),
and other smaller angiotensin fragments. Ang-(1–12) metabolism
by cardiac myocytes was significantly blocked in the presence of
specific enzyme inhibitors for ACE, neprilysin, ACE2, and
chymase. While the hydrolysis of
125I-Ang-(1–12) was found to
be primarily due to ACE and NEP in WKY rats, chymase
contributed to the conversion of
125I-Ang-(1–12) to Ang I and Ang
II in SHR. This new observation is in keeping with the
demonstration of an important role for mast cell derived chymase
in Ang II formation following either decreased expression [29] or
pharmacological blockade of ACE [30] This finding also agrees
with Prosser et al. [29] report that chymostatin completely
inhibited Ang II formation from Ang-(1–12). As discussed
elsewhere, [5,31] differences in the nature of the enzymatic
pathways accounting for Ang-(1–12) metabolism in the studies
reported by Nagata et al. [1] and Prosser et al. [8] may be a result
of increased cellular permeability associated with the isolated
cardiac perfusion procedures use by Prosser et al. (12). The more
controlled preparation employing only cardiac myocytes cultures
rather than the whole organ or the systemic circulation provided a
more precise system for the identification of the differential routes
of Ang-(1–12) processing reported in this study. In addition, the
higher contribution of chymase in Ang-(1–12) metabolism found
in SHR compared to WKY controls is in keeping with previous
findings of increased chymase activity in SHR. [32]
Immunofluorescence staining using a well-characterized Ang-
(1–12) antibody clearly shows the presence of Ang-(1–12) in
neonatal cultured SHR and WKY myocytes. In addition,
angiotensinogen protein but not renin was also detected in these
myocytes by Western blot analysis. These studies further buttress
the hypothesis that Ang-(1–12) may be generated intracellularly
from angiotensinogen as well as incorporated into the myocyte.
In summary, we document the incorporation of Ang-(1–12) and
metabolic pathways of Ang-(1–12) in cardiac myocytes of WKY
and SHR. Increase cellular uptake of Ang-(1–12) in the cardiac
myocytes from SHR is in keeping with our previous demonstration
of elevated values of Ang-(1–12) in the myocardium of SHR. [3]
Since Ang-(1–12) processing was demonstrated by us to occur both
in vivo [5] and in vitro [4] via a non-renin pathway, the current
identification of ACE, NEP, and chymase reveals the enzymatic
pathways contributing to the generation of angiotensin peptides
from Ang-(1–12) in the medium collected from neonatal myocytes.
Materials and Methods
Isolation of Neonatal Cardiac Myocytes
15–18 days pregnant SHR and normotensive WKY mothers
were purchased from Charles River Laboratories Inc. (Wilming-
ton, MA). Neonatal rat ventricular cardiac myocytes of WKY and
SHR pups (1–3 day old) were isolated by proteolytic digestion and
differential plating, as previously described. [33,34] Briefly,
neonatal pups were placed under deep isoflurane (4%) anesthesia
and their hearts were quickly removed and placed into ice cold
Hanks Balanced Salt Solution (HBSS) medium. The myocytes
were isolated from minced ventricles by proteolytic digestion and
differential plating (to separate the myocytes from fibroblast).
Myocytes were collected and maintained in DMEM/F-12
supplemented with 10% FBS, 10 mg/mL insulin, 10 mg/mL
holo-transferrin, 100 mM 5-bromodeoxyuridine (to prevent prolif-
eration of non-myocytes), and antibiotics (ampicillin and strepto-
mycin) in a humidified incubator with an atmosphere of 95% O2,
5%CO2. Myocytes were incubated overnight in the same
DMEM/F-12 medium in the absence of FBS and 5-bromode-
oxyuridine before use for
125I-Ang-(1–12) uptake and metabolism
studies. Cells isolated by this protocol routinely showed positive
staining for anti-sarcomeric myosin (1:100 dilutions, Sigma-
Aldrich Co., St Louis, MO) and no immunoreactivity labeling
with antibodies to alpha-actin, fibronectin, or vimentin (1:100
dilutions, Sigma-Aldrich Co., St Louis, MO).
Ethics Statement
All experimental procedures (Animal Protocol # A09-026
approved on March 11, 2009 by Dr. Mark S. Miller, Chairman of
Animal Care and Use Committee) were performed in accordance
with guidelines set forth by the Institutional Animal Care and Use
Committee of the Wake Forest University School of Medicine.
Cellular Uptake and Metabolism of
125I-Ang-(1–12) Assays
Cellular uptake and metabolism of Ang-(1–12) by WKY and
SHR cultured myocytes were studied under different combina-
tions of RAS inhibitors. To elaborate, lisinopril for ACE, MLN-
4760 for angiotensin-converting enzyme 2 (ACE2), SCH39370 for
neprilysin (NEP) and chymostatin for chymase as detailed in
Table 2.
In cellular uptake studies, twenty-four hour serum deprived
WKY or SHR myocytes, washed twice with serum-free DMEM/
F-12 medium, were exposed to culture medium containing
125I-
Ang-(1–12) (1 nmol/L) at specific activity 3,900 cpm/fmol in the
presence of all RAS inhibitors each added at a concentration of
10 mMa t3 7 uC in a water bath for 0–30 min. Inhibitors were
added 15 min prior to adding the
125I-Ang-(1–12). To determine
the specificity of cellular uptake of radiolabeled
125I-Ang-(1–12),
the cultured cardiac myocytes in some of the experiments, were co
exposed to excess amount of unlabeled Ang-(1–12) [1 mmol/L]
along with
125I-Ang-(1–12) for 30 min at 37uC. Afterward, the
dosing medium was removed and the cells were washed three
times with ice-cold PBS and one time with 0.05 M glycine-HCl
(pH 4.0) to remove the membrane bound
125I-Ang peptides. After
removing the membrane bound
125I-Ang peptides, the cells were
lysed with 1 N NaOH and counted in a gamma counter to
determine the total cellular uptake of
125I-Ang-(1–12). In other
Table 2. Outline of enzyme inhibitors employed in the experiments.
Group Inhibitors added (10 mM each)
No RAS inhibitor group Only peptidases inhibitors (amastatin, bestatin & benzyl succinate) and P-chloromercuribenzoate (PCMB).
All RAS inhibitor group Above inhibitors + RAS inhibitors [lisinopril for ACE, MLN-4760 for ACE2, SCH39370 for NEP and chymostatin for chymase].
Minus RAS inhibitor groups All above inhibitors except one of the RAS inhibitor (lisinopril, SCH39370, MLN-4760 or chymostatin) was omitted at a time from the
reaction mixture.
Abbreviations as in text.
doi:10.1371/journal.pone.0015759.t002
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125I-Ang-(1–12) in the absence and presence of RAS inhibitors for
60 min at 37uC as described above. At the end of exposure time,
the washed cells were collected in 1 mL of acid-ethanol (0.1N
HCl+80% ethanol) and stored at 280uC to analyze the cellular
uptake of
125I-Ang-(1–12) by HPLC. Total cellular protein
concentration were measured by Bradford Reagent using bovine
serum albumin (BSA) as standard and the total cellular counts
were normalized in terms of mg protein.
For
125I-Ang-(1–12) metabolism study, the cultured myocytes
(WKY or SHR) were preincubated for 15 min under various
combinations of RAS and peptidases inhibitors (10 mmol/L of each)
as described above. After preincubation of myocytes with the
inhibitors,
125I-Ang-(1–12) (1 nmol/L) was added to reaction medium
a n di n c u b a t e df o r6 0m i na t3 7 uC in the water bath. At the end of
incubationtime,exposedmediumandcardiacmyocyteswere collected
separately and processed for HPLC analysis as described below.
HPLC Analysis of Ang-(1–12) Metabolic Products in
Medium and in Cardiac Myocytes
Cellular uptake of
125I-Ang-(1–12) by cardiac myocytes and
their metabolic products in cell lysate and dosing medium were
analyzed by HPLC as previously described. [35,36] The medium
from the cell cultures was removed and mixed with 1% of
phosphoric acid and stored at 280uC until processing the samples
for Ang contents [Ang-(1–12), Ang I, Ang II and Ang-(1–7)] by
HPLC. After removing the dosing medium, myocytes were
washed three times with ice-cold PBS and one time with 0.05 M
glycine-HCl (pH 4) to remove the membrane bound
125I-Ang.
After removing the membrane bound
125I-Ang-(1–12), the
myocytes were scraped using a cell lifter in 1 mL of acid-ethanol
(0.1N HCl + 80% ethanol). The scraped cells were immediately
frozen and stored at 280uC till processing the samples to detect
the cellular
125I-Ang content by HPLC.
Before using the samples for HPLC analysis, the cell lysate and
medium were passed through Sep-Pak C18 cartridge columns
(Waters Corp., Milford, MA) to collect the
125I-labeled Ang-(1–12)
metabolic products. Briefly, cells and medium (stored at 280uC)
were thawed in ice and the cell lysate were briefly sonicated for
10 sec. The lysed cells were centrifuged at 28,000 rpm for 15 min
to remove the cell membrane and debris. The clear supernatant
and the medium were diluted with 9x vol. of 0.1% trifluoroacetic
acid (TFA) and were passed through activated Sep-Paks by
gravity. The columns were first washed with 10 mL of 0.1% TFA
and then with 5 mL of MilliQ water. After washing the column,
the bound
125I-labeled Ang-(1–12) metabolic products were eluted
with 80% methanol + 0.1% TFA. Finally, Sep-Pak eluted samples
were analyzed by HPLC to detect the
125I-Ang-(1–12) metabolic
products. We used a linear gradient from 10% to 50% mobile
phase B at a flow rate of 0.35 mL/min at ambient temperature.
The solvent system consisted of 0.1% phosphoric acid (mobile
phase A) and 80% acetonitriles/0.1% phosphoric acid (mobile
phase B). The eluted
125I products were monitored by an in-line
flow-through gamma detector (BioScan). Products were identified
by comparison of retention times to synthetic [
125I] standard
peptides and the data were analyzed with Shimadzu (version 7.2.1)
acquisition software. The iodination of rat Ang-(1–12) and other
angiotensins was performed as described previously. [35,36]
Contribution of specific enzymes (ACE, NEP, ACE or
chymase)
The contribution of ACE, NEP, ACE2 or chymase to the hy-
drolysis of
125I-Ang-(1–12) substrate were analyzed by measuring
the amount of Ang products formation in the cultured medium
after exposing the cells in the presence of all RAS inhibitors
cocktail and in the absence of specific enzyme inhibitors for ACE,
NEP, ACE2 or chymase only (as described above). Medium was
collected after exposing the WKY and SHR cells for 60 min at
37uC under two different enzyme inhibitors conditions (+All RAS
inhibitors versus minus ACE/NEP/ACE2/chymase inhibitor only)
and were analyzed by HPLC as described above. The enzyme
activity was calculated based on amount of 1 nM of
125I-Ang-(1–
12) substrate added to the reaction mixture and metabolized into
final products by specific RAS enzyme. The protein content of
each well was determined by Bradford Reagent using BSA as
standard protein. Experiments were performed three or more
times and the enzyme activity values were reported as fmoles of
Ang product formation from
125I-Ang-(1–12) substrate per min per
mg protein (fmol?mg protein
21?min
21).
Localization of Endogenous Synthesis of Ang-(1–12) in
Cultured Cardiac Myocytes
The presence of Ang-(1–12) in the cultured cardiac myocytes
were evaluated by immunofluorescent microscopy using a protein
A column purified anti-rabbit rat Ang-(1–12) primary antibody
(1:100 dilution). We showed previously that the Ang-(1–12)
antibody did not cross-react with angiotensinogen, Ang I, Ang II
and Ang-(1–7) and the fluorescence Cy2 secondary antibody
(Jackson ImmunoResearch Laboratory, Inc., West Grove, PA). [3]
Cardiac myocytes from WKY and SHR were cultured as
described above in 8-well chambered slides. Myocytes (maintained
in serum-deprived medium for 48 hours) were then washed three
times with PBS, fixed in 4% paraformaldehyde for 15 min and
permeabilized in 0.1% Triton X-100 in 4% paraformaldehyde for
another 15 min. The fixed cells were incubated overnight at 4uC
with the purified rat Ang-(1–12) antibody (1:100 dilutions). The
next day, the cells were washed three times with PBS and
incubated with the fluorescence tagged secondary antibody
(Cy
Tm2-conjugated AffiniPure Donkey Anti-Rabbit IgG; 1:200
dilutions) for 1 h at room temperature. The secondary antibody
was washed three times with PBS and cells were covered with
cover slip after adding one drop of ProLong Gold antifade
reagents with DAPI (49–6-diamidino-2-phenylindole; a blue
fluorescent probe widely use to stain DNA in the nuclei of cells).
The resultant fluorescent immunoreactive staining of endogenous
rat Ang-(1–12) in cardiac myocytes of WKY and SHR cells were
visualized using a fluorescent microscope (Leica DM 4000B, Leica
Microsystems, Wetzlar, Germany). The immunofluorescent stain-
ing was repeated three or more times in cultured cardiac myocytes
isolated from different batches of WKY and SHR neonatal pups.
Western blot analysis of Angiotensinogen and Renin in
Cultured Cardiac Myocytes
The expression of angiotensinogen protein in neonatal cultured
cardiac myocytes was assessed by immunoblot. Myocytes were
isolated and maintained as describe above. Before collecting the
myocytes for angiotensinogen protein expression, the cells were
cultured for 48 hours in serum-deprived medium. Angiotensino-
gen protein expression was assessed in total cell lysate by using an
antibody directed against an epitope on the NH2-terminus region
of the protein (residues 44–56) which detects both Ang I-
containing and des-Ang I forms of the protein. [37] The myocytes
cell lysate (50 mg protein) were separated by gel electrophoresis
and transferred to polyvinylidene difluoride membranes (PVDF).
The PVDF membranes were probed with an antibody against rat
angiotensinogen protein (1:1000 dilutions). Densities of the 60-KD
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mined with a MCID imaging system (MCID Elite 7.0, Imaging
Research Inc., St. Catharine, ON, Canada). The expression of
renin in neonatal cultured myocytes was also assessed using an
antibody against rat renin (1:1000 dilution) obtained from Dr.
Tadashi Inagami as described above.
Reagents
Angiotensin-(1–12) (.99% purity) was purchased from Gen-
Script USA Inc. (Piscataway, NJ). DMEM/F12, Hanks’ Balance
Salt Solution (HBSS), Leibovitz’s L-15 medium, fetal bovine
serum (FBS), penicillin and streptomycin were purchased from
GIBCO Invitrogen (Gaithersburg, MD). ProLong Gold antifade
reagent with DAPI was purchased from Invitrogen (Molecular
Probes, Inc., Eugene, OR). Fluorescent secondary antibody (Cy
Tm
2-conjugated AffiniPure Donkey Anti-Rabbit IgG) and normal
Donkey serum were purchased from Jackson ImmunoResearch
Laboratories, Inc. (West Grove, PA). Collagenase, trypsin and
soybean trypsin inhibitors were purchased from Worthington
Biochemical Corporation (Lakewood, NJ). Lisinopril (ACE
inhibitor) and SCH39370 (neprilysin inhibitor) were obtained
from Merck (West Point, PA). MLN-4760 (ACE2 inhibitor) was
obtained from Millennium Pharmaceuticals (Cambridge, MA).
Chymostatin (chymase inhibitor), amastatin, bestatin and benzyl
succinate and PCMB were purchased from Sigma-Aldrich Co. (St.
Louis, MO). Radioactive
125I was purchased from PerkinElmer
Life and Analytical Sciences, Inc. (Waltham, Massachusetts). All
other chemicals used in this study were of analytical grade and
were obtained from Sigma (St. Louis, MO), and Fisher Scientific
(Atlanta, GA).
Statistical Analysis
Experiments were repeated independently three or more times.
All values are reported as mean 6 SE. The Student’s t-test and
repeated-measures ANOVA followed by a Turkey’s post hoc test
for multiple comparisons were used to determine significant
differences at a probability of 0.05 using GraphPad Prism 5.0
software (San Diego, CA).
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